UNSPSC 51412701: Nafronyl or naftidrofuryl

This classification denotes a vasodilating agent and serotonin antagonist with the molecular formula C24H33NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 42H8PQ0NMJ, chemically known as 2-furanpropionic acid, tetrahydro-.alpha.-(1-naphthylmethyl)-, 2-(diethylamino)ethyl esteroxalate (1:1) but generally known as nafronyl, which bears US NIH Compound Identifier 4417. European Medicines Agency schedules Naftidrofuryl in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09130MIG.

UNSPSC 51412701 Nafronyl or naftidrofuryl is a Commodity code for emergency and acute-care medications supplied to state and local health systems, fire departments, and pharmacy benefit programs. State and local governments soliciting under this code procure pharmaceuticals for emergency medical services, hospital systems, and multi-state health programs, often through sealed-bid and cooperative purchasing vehicles that bundle generic drugs and over-the-counter products with established wholesaler networks and cGMP and Drug Supply Chain Security Act compliance requirements.

Recent activity spans city fire departments, state health agencies, and multi-state cooperative purchasing alliances. The City of Tampa's Purchasing Department issued IFB 26P00188 in April 2026 for Advanced Life Support Medications (Labetalol, Epinephrine, Adenosine, and Diltiazem) for Tampa Fire Rescue, with bids due April 8, 2026 and an estimated contract value of $40,000 under a one-year term with two optional one-year renewals and a Small Local Business Enterprise sheltered-market designation offering a 5 percent bid discount. The Texas Health and Human Services Commission issued RFI HHS0017013 in April 2026 to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, seeking information on direct contracting outside traditional pharmacy benefit managers and group purchasing organizations. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued an RFP (S1070000015802) in January 2026 with a March 26, 2026 response deadline for generic multi-source pharmaceuticals and OTC products to be distributed across participating state and local government facilities in Minnesota and Oregon, with contracts effective July 1, 2026 and vendor evaluation weighted 75 percent on price competitiveness, requiring cGMP certification, Drug Supply Chain Security Act compliance, and relationships with authorized wholesalers (AmerisourceBergen/Cencora, Cardinal Health, and Morris & Dickson).